We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vume... Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. Show more
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...
CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the “Board”) today announced the appointments of two new independent directors, Lloyd B...
Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational...
Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain PR Newswire TOKYO and CAMBRIDGE, Mass., Aug. 22, 2024 FOR GLOBAL MEDIA AND JOURNALISTS OUTSIDE THE EMEA REGION In...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.695 | -1.84740762962 | 200.01 | 200.37 | 188.78 | 1742857 | 195.74108622 | CS |
4 | -9.505 | -4.6181129142 | 205.82 | 206.7 | 188.78 | 1106744 | 198.49666436 | CS |
12 | -28.715 | -12.7605208194 | 225.03 | 238 | 188.78 | 1001597 | 207.84564062 | CS |
26 | -17.185 | -8.04918032787 | 213.5 | 238 | 188.78 | 1076799 | 212.92312937 | CS |
52 | -62.125 | -24.0384615385 | 258.44 | 269.4312 | 188.78 | 1098701 | 226.18445577 | CS |
156 | -94.515 | -32.4983667435 | 290.83 | 319.76 | 187.16 | 1155473 | 244.29291025 | CS |
260 | -34.965 | -15.1180387409 | 231.28 | 468.2499 | 187.16 | 1346844 | 269.48897954 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions